Frieß W - Search Results

1

Application of interpretable artificial neural networks to early monoclonal antibodies development.

Gentiluomo L, Roessner D, Augustijn D, Svilenov H, Kulakova A, Mahapatra S, Winter G, Streicher W, Rinnan Å, Peters GHJ, Harris P, Frieß W. Gentiluomo L, et al. Among authors: friess w. Eur J Pharm Biopharm. 2019 Aug;141:81-89. doi: 10.1016/j.ejpb.2019.05.017. Epub 2019 May 18. Eur J Pharm Biopharm. 2019. PMID: 31112768

2

Impact of freezing procedure and annealing on the physico-chemical properties and the formation of mannitol hydrate in mannitol-sucrose-NaCl formulations.

Hawe A, Friess W. Hawe A, et al. Among authors: friess w. Eur J Pharm Biopharm. 2006 Nov;64(3):316-25. doi: 10.1016/j.ejpb.2006.06.002. Epub 2006 Jun 23. Eur J Pharm Biopharm. 2006. PMID: 16875806

3

Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.

Schüle S, Friess W, Bechtold-Peters K, Garidel P. Schüle S, et al. Among authors: friess w. Eur J Pharm Biopharm. 2007 Jan;65(1):1-9. doi: 10.1016/j.ejpb.2006.08.014. Epub 2006 Sep 1. Eur J Pharm Biopharm. 2007. PMID: 17034996

4

A model describing the effect of enzymatic degradation on drug release from collagen minirods.

Metzmacher I, Radu F, Bause M, Knabner P, Friess W. Metzmacher I, et al. Among authors: friess w. Eur J Pharm Biopharm. 2007 Sep;67(2):349-60. doi: 10.1016/j.ejpb.2007.02.013. Epub 2007 Feb 25. Eur J Pharm Biopharm. 2007. PMID: 17408937

5

Development of HSA-free formulations for a hydrophobic cytokine with improved stability.

Hawe A, Friess W. Hawe A, et al. Among authors: friess w. Eur J Pharm Biopharm. 2008 Feb;68(2):169-82. doi: 10.1016/j.ejpb.2007.04.018. Epub 2007 May 5. Eur J Pharm Biopharm. 2008. PMID: 17574398

6

A critical evaluation of self-interaction chromatography as a predictive tool for the assessment of protein-protein interactions in protein formulation development: a case study of a therapeutic monoclonal antibody.

Le Brun V, Friess W, Bassarab S, Mühlau S, Garidel P. Le Brun V, et al. Among authors: friess w. Eur J Pharm Biopharm. 2010 May;75(1):16-25. doi: 10.1016/j.ejpb.2010.01.009. Epub 2010 Jan 25. Eur J Pharm Biopharm. 2010. PMID: 20102739

7

Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation.

Schiefelbein L, Keller M, Weissmann F, Luber M, Bracher F, Friess W. Schiefelbein L, et al. Among authors: friess w. Eur J Pharm Biopharm. 2010 Nov;76(3):342-50. doi: 10.1016/j.ejpb.2010.08.012. Epub 2010 Sep 9. Eur J Pharm Biopharm. 2010. PMID: 20816956

8

Influence of pH and ionic strength on IgG adsorption to vials.

Mathes J, Friess W. Mathes J, et al. Among authors: friess w. Eur J Pharm Biopharm. 2011 Jun;78(2):239-47. doi: 10.1016/j.ejpb.2011.03.009. Epub 2011 Mar 21. Eur J Pharm Biopharm. 2011. PMID: 21421047

9

Residual transglutaminase in collagen - effects, detection, quantification, and removal.

Schloegl W, Klein A, Fürst R, Leicht U, Volkmer E, Schieker M, Jus S, Guebitz GM, Stachel I, Meyer M, Wiggenhorn M, Friess W. Schloegl W, et al. Among authors: friess w. Eur J Pharm Biopharm. 2012 Feb;80(2):282-8. doi: 10.1016/j.ejpb.2011.10.018. Epub 2011 Nov 4. Eur J Pharm Biopharm. 2012. PMID: 22079174

10

Particles in therapeutic protein formulations, Part 1: overview of analytical methods.

Zölls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A. Zölls S, et al. Among authors: friess w. J Pharm Sci. 2012 Mar;101(3):914-35. doi: 10.1002/jps.23001. Epub 2011 Dec 8. J Pharm Sci. 2012. PMID: 22161573 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters